Valid

YY/T 1224-2014Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer(Fluorescent in situ hybridization) (English PDF)

膀胱癌细胞相关染色体及基因异常检测试剂盒(荧光原位杂交法)

Preview PDF

This is a limited preview

Buy now to download the full PDF (15 pages)

Need quotation for your management?

Get a formal quotation for YY/T 1224-2014 in 30 minutes.

Issued by

NMPA

Level / Type

Industry · Recommended

Issue date

June 17, 2014

Implementation date

July 1, 2015

Scope

YY/T 1224-2014 is the English-translated version of 膀胱癌细胞相关染色体及基因异常检测试剂盒(荧光原位杂交法).

YY/T 1224-2014 is the Chinese pharmaceutical industry standard for the kit that detects the chromosome and gene abnormalities related to bladder cancer by fluorescence in situ hybridization, as used on cells from urine.

It specifies the definition and the composition of the kit, the requirements, the test methods, the marking, the labelling, the instructions and the rules for packaging, transport and storage, covering the probes and their specificity, the signal and the background, the agreement with reference materials, the repeatability and the stability. Issued on 17 June 2014, it has applied since 1 July 2015.

Found what you need?

Document preview — YY/T 1224-2014

National Standard of the People's Republic of China

ICS
11.100
Classification
C 44

Issued by: National Medical Products Administration of the People's Republic of China

Contents

  • Foreword
  • 1 Scope
  • 2 Normative references
  • 3 Terms and Definitions
  • 4 Requirements

Foreword

This standard was drafted in accordance with GB/T 1.1-2009 given rules.

1 Scope

This standard specifies the bladder cancer-related chromosomal abnormality detection kit (fluorescence in situ hybridization) the definition and composition, to Requirements, test methods, marking, labeling, instructions, packaging, transport and storage.

This standard applies to the CSP3, CSP7, CSP17, GLP9 corresponding sites of four kinds of fluorescence in situ hybridization probe and counterstain composed by Test sample (usually urine smears) on the 3rd, 7th, 17th chromosome aneuploidy increases and P16 gene locus on chromosome 9 Missing the point, so the diagnosis of bladder cancer kits. This standard does not apply to.

a) In immunohistochemistry diagnostic methods as the basic principle for bladder cancer diagnosis kit;

Labeled Immunoassays b) by ELISA analysis as the basic principle for bladder cancer diagnosis kit.

2 Normative references

The following documents for the application of this document is essential. For dated references, only the dated version suitable for use herein Member. For undated references, the latest edition (including any amendments) applies to this document.

GB/T 191 Packaging - Pictorial signs

3 Terms and Definitions

The following terms and definitions apply to this document.

3.1 Fluorescence in situ hybridization fluorescentinsituhybridization; FISH

According to the principle of complementary base pairing with the target nucleic acid fragment DNA pairing (probe) on the labeling fluorescent dye, and the probe is to be tested Nucleic acid fragments corresponding materials under certain conditions specific binding (hybridizing) to form a double-stranded nucleic acid, fluorescence microscopy and recorded by means of shape A type of hybrid duplexes, the number, the sample to be tested to determine whether or not the normal method for detecting target DNA.

3.2 Detection kit for analysis of related chromosome and gene abnormalities in bladder cancer

Bladder cancer-related chromosomal abnormalities and gene detection kit (fluorescence in situ hybridization) detectionkitforanalysisof relatedchromosomeandgeneabnormalitiesinbladdercancer (fluorescentinsituhybridization)

By the CSP3, CSP7, CSP17 and GLP9 corresponding sites of a total of four kinds of fluorescence in situ hybridization probes (hereinafter referred to as. Probe) and counterstain And other auxiliary agents composed by the 3rd detected sample to be tested, No. 7, No. 17 chromosome aneuploidy and increased chromosome 9 P16 group Due to lack of sites for bladder cancer diagnosis kit (hereinafter. the kit).

4 Requirements

4.1 Appearance

The kit packaging should be complete, no damage, marked complete, clear; each liquid reagent should be clearly labeled, leak-free, color should be consistent with the manufacturer

......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 15 pages — is available in the English PDF.

Referenced standards

Similar standards

How to Download YY/T 1224-2014

  1. 1

    Add to cart

    Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.

  2. 2

    Checkout

    Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).

  3. 3

    Fast delivery

    After payment you'll receive an email confirmation. The English PDF is sent to the same address, usually within minutes and at the latest within 1 business day.

  4. 4

    Invoice included

    A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.

Related Standards

English PDF
15 pages
Fast delivery
Invoice included
View Cart

Secure payment via Stripe

Payments accepted

VisaMastercardAmerican ExpressApple PayGoogle PayStripe

YY/T 1224-2014

$145.00